ArticleJournal of clinical medicine2023

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System.

Yang Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.